| Name | Title | Contact Details |
|---|
To be Hansei is to reflect on the past, learn from mistakes, and commit to doing better in the future. To stop Hansei is to stop learning. Hansei Solutions helps behavioral healthcare facilities nationwide do it better, combining full-service revenue cycle management technology with a personal touch to forge lasting and strategic partnerships. Simply put, Hansei enables providers to collect more, save more, remain compliant, and make more informed decisions impacting their growth and bottom line.
Acuitec is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Birmingham, AL. To find more information about Acuitec, please visit www.acuitec.com
Occupational Environmental Health Solutions is a Chatham, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic